# A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Study · id `cardio:ct-nct06065540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06065540](<https://clinicaltrials.gov/study/NCT06065540>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06065540

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2734 participants.

## Technical summary

Registry record NCT06065540. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-27 (actual); primary completion 2025-11-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2734 participants (enrolled count; ClinicalTrials.gov record NCT06065540, source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)
- Started: 2023-09-27 (actual) (ClinicalTrials.gov record NCT06065540, source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)
- Primary completion: 2025-11-19 (actual) (ClinicalTrials.gov record NCT06065540, source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)
- Completion: 2026-01-06 (actual) (ClinicalTrials.gov record NCT06065540, source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Denmark; Finland; Germany; Greece; Hungary; India; Israel; Italy; Japan; Mexico; Poland; Romania; Serbia; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT06065540, source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06065540-2026-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Acronym: REIMAGINE 2
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Cagrilintide
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo cagrilintide
- Intervention (Drug): Placebo semaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study (`cardio:pubmed-42251859`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2f697637255f249d7d9b450db7fc7ac01e38233d9f30361793711afc278f4e92
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
